The class 1 new drug X842 that used to treat gastroesophageal reflux disease, has successfully completed the EU phase I clinical trial in Sweden in February 2018. The result showed that X842 was well tolerated in healthy volunteers with no serious adverse effect(SAE) or adverse effect(AE) that caused the volunteers to withdraw from the research.